Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 10/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 10/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 9/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 9/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566880 | 1.00 | ABCC9 (0.35) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL13054725 | 0.93 | ABCC9 (0.34) | ABCC9KCNJ11ABCC8KCNJ8LMNA | |
| SCHEMBL7566911 | 0.93 | ABCC9 (0.34) | ABCC9KCNJ11ABCC8KCNJ8LMNA | |
| SCHEMBL13054967 | 0.91 | MEN1 (0.35) | MEN1KMT2AESR1 | |
| SCHEMBL7541540 | 0.91 | MEN1 (0.35) | MEN1KMT2AESR1 | |
| SCHEMBL7583487 | 0.88 | ABCC9 (0.32) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL13081820 | 0.88 | MEN1 (0.34) | MEN1KMT2AESR1 | |
| SCHEMBL14105367 | 0.88 | MEN1 (0.34) | MEN1KMT2AESR1 | |
| SCHEMBL7572424 | 0.85 | AR (0.37) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL13054170 | 0.85 | AR (0.37) | ABCC9KCNJ11ABCC8KCNJ8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| WO-2008103351-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | ABCC9 2010/4885KCNJ11 4379/4885ABCC8 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.